A new set of experiments in mice confirms that a brain receptor associated with the reinforcing effects of marijuana also helps to stimulate the rewarding and pleasurable effects of alcohol. The research, which was conducted at the U.S. Department of Energy’s Brookhaven National Laboratory and was published online September 2, 2005 by the journal Behavioural Brain Research, confirms a genetic basis for susceptibility to alcohol abuse and also suggests that drugs designed to block these receptors could be useful in treatment.

“These findings build on our understanding of how various receptors in the brain’s reward circuits contribute to alcohol abuse, help us understand the role of genetic susceptibility, and move us farther along the path toward successful treatments,” said Brookhaven’s Panayotis (Peter) Thanos, lead author of this study and many others on “reward” receptors and drinking (see: this release and , www.bnl.gov/thanoslab).

International behavioral neuroscience society - ninth annual meeting. - Related Articles
International behavioral neuroscience society - ninth annual meeting.
IDrugs. 2000 Jul;3(7):743-4
Authors: Agmo A
The main thrust of the meeting was, as always, basic research in behavioral neuroscience defined in a broad sense. Learning and memory, feeding and drinking, reward mechanisms, development of the CNS, anxiety and stress were the main topics covered. In a public lecture associated with the meeting, Larry Reid (Rensselaer Polytechnic Institute, Troy, NY, USA) reviewed the quite compelling evidence in favor of the effectiveness of naltrexone for preventing relapse in former alcoholics. He also presented preclinical data demonstrating the remarkable effects of naltrexone given together with isradipine (Novartis AG) in blocking the rewarding effects of cocaethylene. This combination of drugs could thereby constitute a treatment for alcoholism complicated by cocaine abuse. Of potential therapeutic interest was also the description of the preclinical pharmacology and a phase II trial of a new cholinesterase inhibitor, methanesulfonyl fluoride (University of Texas). The possible physiological functions of sigma opioid receptors and the pharmacological properties of sigma receptor ligands were discussed at one of the symposia. Among the subjects covered were the potential use of sigma1 antagonists in the treatment of cocaine addiction and the efficiency of sigma1 agonists for preventing the decline in cognitive functions associated with old age.